Universität zu Köln

Altunay, Betuel, Morgenroth, Agnieszka, Beheshti, Mohsen, Vogg, Andreas, Wong, Nicholas C. L., Ting, Hong Hoi, Biersack, Hans-Juergen, Stickeler, Elmar and Mottaghy, Felix M. . HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. Eur. J. Nucl. Med. Mol. Imaging. NEW YORK: SPRINGER. ISSN 1619-7089

Full text not available from this repository.

Abstract

Purpose The aim of the present paper is to review the role of HER2 antibodies, affibodies and nanobodies as vehicles for imaging and therapy approaches in breast cancer, including a detailed look at recent clinical data from antibody drug conjugates and nanobodies as well as affibodies that are currently under development. Results Clinical and preclinical studies have shown that the use of monoclonal antibodies in molecular imaging is impaired by slow blood clearance, associated with slow and low tumor uptake and with limited tumor penetration potential. Antibody fragments, such as nanobodies, on the other hand, can be radiolabelled with short-lived radioisotopes and provide high-contrast images within a few hours after injection, allowing early diagnosis and reduced radiation exposure of patients. Even in therapy, the small radioactively labeled nanobodies prove to be superior to radioactively labeled monoclonal antibodies due to their higher specificity and their ability to penetrate the tumor. Conclusion While monoclonal antibodies are well established drug delivery vehicles, the current literature on molecular imaging supports the notion that antibody fragments, such as affibodies or nanobodies, might be superior in this approach.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Altunay, Betuel UNSPECIFIED UNSPECIFIED UNSPECIFIED Morgenroth, Agnieszka UNSPECIFIED UNSPECIFIED UNSPECIFIED Beheshti, Mohsen UNSPECIFIED UNSPECIFIED UNSPECIFIED Vogg, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Wong, Nicholas C. L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ting, Hong Hoi UNSPECIFIED UNSPECIFIED UNSPECIFIED Biersack, Hans-Juergen UNSPECIFIED UNSPECIFIED UNSPECIFIED Stickeler, Elmar UNSPECIFIED UNSPECIFIED UNSPECIFIED Mottaghy, Felix M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-311600
DOI:	10.1007/s00259-020-05094-1
Journal or Publication Title:	Eur. J. Nucl. Med. Mol. Imaging
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1619-7089
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SINGLE-DOMAIN ANTIBODY; EMITTING RADIOTHERAPEUTIC AGENT; TRASTUZUMAB EMTANSINE T-DM1; HER2 RECEPTOR EXPRESSION; IN-VIVO; PRECLINICAL EVALUATION; MONOCLONAL-ANTIBODY; RESIDUALIZING LABEL; ANTI-HER2 NANOBODY; N-SUCCINIMIDYL Multiple languages Radiology, Nuclear Medicine & Medical Imaging Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/31160